The duration time of treatment (our study: 6.4 ± 4.4 months) ALK‐rearranged SCC was shorter than those in previous clinical trials of ALK‐rearranged ADC studies (PROFILE1007:7.7 months, PROFILE1014:10.9 months; ALESIANCT02838420:14.6 months), 34, 35 suggesting that outcomes are worse for ACC as compared to the ADC patient when ALK inhibitors are used. This evidence concerns the gene ALK and adrenal cortex carcinoma.